Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Ai-qin Niu, Liang-jun Xie, Hui Wang, Bing Zhu & Sheng-qi Wang. (2016) Prediction of selective estrogen receptor beta agonist using open data and machine learning approach. Drug Design, Development and Therapy 10, pages 2323-2331.
Read now
Read now
Vineetha Koroth Edavana, Xinfeng Yu, Ishwori B Dhakal, Suzanne Williams, Baitang Ning, Ian T Cook, David Caldwell, Charles N Falany & Susan Kadlubar. (2011) Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1. Pharmacogenomics and Personalized Medicine 4, pages 137-145.
Read now
Read now
Ryan A Dick & Thomas W Kensler. (2002) Chemoprotective potential of phase 2 enzyme inducers. Expert Review of Anticancer Therapy 2:5, pages 581-592.
Read now
Read now
Articles from other publishers (26)
Mengwu Pan, Valeria Solozobova, Nane C. Kuznik, Nicole Jung, Simone Gräßle, Victor Gourain, Yvonne M. Heneka, Christina A. Cramer von Clausbruch, Olaf Fuhr, Ravi S. N. Munuganti, Danilo Maddalo, Christine Blattner, Antje Neeb, Adam Sharp, Laura Cato, Carsten Weiss, Rinath M. Jeselsohn, Veronique Orian-Rousseau, Stefan Bräse & Andrew C. B. Cato. (2023) Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. Cancer Research Communications 3:7, pages 1378-1396.
Crossref
Crossref
Sarmistha Mitra, Raju Dash, Md. Sohel, Apusi Chowdhury, Yeasmin Akter Munni, Md. Chayan Ali, Md. Abdul Hannan, Md. Tofazzal Islam & Il Soo Moon. (2023) Targeting Estrogen Signaling in the Radiation-induced Neurodegeneration:
A Possible Role of Phytoestrogens. Current Neuropharmacology 21:2, pages 353-379.
Crossref
Crossref
Mark S. Sundrud & Anjana Rao. (2008) Regulation of T Helper 17 Differentiation by Orphan Nuclear Receptors: It's Not Just RORγt Anymore. Immunity 28:1, pages 5-7.
Crossref
Crossref
VijayaLaxmi Deshmane, S. Krishnamurthy, Allen S. Melemed, Patrick Peterson & Aman U. Buzdar. (2007) Phase III Double-Blind Trial of Arzoxifene Compared With Tamoxifen for Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology 25:31, pages 4967-4973.
Crossref
Crossref
Emrah Yavuz, Mesut Oktem, Ibrahim Esinler, Serap Arat Toru & Hulusi B. Zeyneloglu. (2007) Genistein causes regression of endometriotic implants in the rat model. Fertility and Sterility 88:4, pages 1129-1134.
Crossref
Crossref
Kazuhiro Matsui. (2007) Combination of receptor-binding assays and designed mutant receptors for discerning agonists and antagonists. Journal of Pharmaceutical and Biomedical Analysis 43:3, pages 822-828.
Crossref
Crossref
Hye-Sook Seo, David G. DeNardo, Yves Jacquot, Ioanna Laïos, Doris Salazar Vidal, Carmen Rojas Zambrana, Guy Leclercq & Powel H. Brown. (2006) Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Research and Treatment 99:2, pages 121-134.
Crossref
Crossref
Raymond E Farah, Nicola M Makhoul, Rola E Farah & Moshe D Shai. (2004) Fatal Venous Thromboembolism Associated with Antipsychotic Therapy. Annals of Pharmacotherapy 38:9, pages 1435-1438.
Crossref
Crossref
Cecilie T Freddie, Gitte L Christensen & Anne E Lykkesfeldt. (2004) A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene. Molecular and Cellular Endocrinology 220:1-2, pages 97-107.
Crossref
Crossref
Cecilie T Freddie, Søren S Larsen, Monica Bartholomæussen & Anne E Lykkesfeldt. (2004) The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Molecular and Cellular Endocrinology 219:1-2, pages 27-36.
Crossref
Crossref
Julia A. Lawrence & Kapil Dhingra. 2004. Cancer Chemoprevention. Cancer Chemoprevention
195
208
.
Yael Paran, Swetlana A. Adansky-Boldin, Raanan Margalit & Hadassa Degani. (2003) Parametric MRI of Water Diffusion in Breast Cancer. Israel Journal of Chemistry 43:1-2, pages 103-114.
Crossref
Crossref
S. Miedlich, K. Krohn & R. Paschke. (2003) Update on genetic and clinical aspects of primary hyperparathyroidism. Clinical Endocrinology 59:5, pages 539-554.
Crossref
Crossref
M. Piccart, L.M. Parker & K.I. Pritchard. (2003) Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Annals of Oncology 14:7, pages 1017-1025.
Crossref
Crossref
Norman S. Radin. (2003) Designing anticancer drugs via the achilles heel: ceramide, allylic ketones, and mitochondria. Bioorganic & Medicinal Chemistry 11:10, pages 2123-2142.
Crossref
Crossref
Yuhua Z. Farnell & Nancy H. Ing. (2003) Myometrial effects of selective estrogen receptor modulators on estradiol-responsive gene expression are gene and cell-specific. The Journal of Steroid Biochemistry and Molecular Biology 84:5, pages 527-536.
Crossref
Crossref
Linda Workman. (2003) Cáncer de mama: Nuevas estrategias para combatir un viejo enemigo. Nursing (Ed. española) 21:4, pages 22-27.
Crossref
Crossref
Suzanne D. Conzen. (2003) Current Status of Selective Estrogen Receptor Modulators (SERMs). The Cancer Journal 9:1, pages 4-14.
Crossref
Crossref
Dalia Rivenzon-Segal, Raanan Margalit & Hadassa Degani. (2002)
Glycolysis as a metabolic marker in orthotopic breast cancer, monitored by in vivo
13
C MRS
. American Journal of Physiology-Endocrinology and Metabolism 283:4, pages E623-E630.
Crossref
Crossref
M. LINDA WORKMAN. (2002) Breast cancer. Nursing 32:10, pages 58-63.
Crossref
Crossref
Norman S Radin. (2002) Cancer progression in the kidney and prostate: vital roles of sphingolipids in chemotherapy. Urology 60:4, pages 562-568.
Crossref
Crossref
Mario Vignali, Mirco Infantino, Roberta Matrone, Ilda Chiodo, Edgardo Somigliana, Mauro Busacca & Paola Viganò. (2002) Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertility and Sterility 78:4, pages 665-678.
Crossref
Crossref
M. T. Littleton‐Kearney, N. L. Ostrowski, D. A. Cox, M. I. Rossberg & P. D. Hurn. (2006) Selective Estrogen Receptor Modulators: Tissue Actions and Potential for CNS Protection. CNS Drug Reviews 8:3, pages 309-330.
Crossref
Crossref
F. López de Castro & J. Rodríguez Alcalá. (2002) Quimioprevención del cáncer de mama. SEMERGEN - Medicina de Familia 28:2, pages 80-83.
Crossref
Crossref
BARBARA K. DUNN, MARIETTA ANTHONY, SHERRY SHERMAN & JOSEPH P. COSTANTINO. (2006) Conclusions. Annals of the New York Academy of Sciences 949:1, pages 352-365.
Crossref
Crossref
Amy I. D'Orazio & Joyce O'Shaughnessy. (2001) Arzoxifene: (LY353381) A Novel Selective Estrogen Receptor Modulator with Activity in Breast Cancer. Clinical Breast Cancer 2:3, pages 188-189.
Crossref
Crossref